Mohnish Pabrai's MASSIVE Investment in AMR stock spotlights Amarin's FDA approval for a key heart drug. CEO John Thero discusses mixed results in drug trials, yet analysts remain bullish, predicting AMRN could hit $15. Investors eye Amarin's potential in the heart health market, balancing risks with potential rewards.